A window of opportunity trial evaluating intratumoral injection of Copaxone® in patients with percutaneously accessible tumors.
Saved in:
| Title: | A window of opportunity trial evaluating intratumoral injection of Copaxone® in patients with percutaneously accessible tumors. |
|---|---|
| Authors: | Baranda JC; Clinical Research Center, University of Kansas Comprehensive Cancer Center, Fairway, KS, USA., Mohyuddin GR; Division of Hematology and Hematological Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Bur AM; Department of Otolaryngology-Head and Neck Surgery, University of Kansas Medical Center, Kansas City, KS, USA., Shnayder Y; Department of Otolaryngology-Head and Neck Surgery, University of Kansas Medical Center, Kansas City, KS, USA., Sweeney KR; Department of Orthopedic Surgery and Sports Medicine, Sarcoma Center, University of Kansas Comprehensive Cancer Center, Kansas City, KS, USA., Kakarala K; Department of Otolaryngology-Head and Neck Surgery, University of Kansas Medical Center, Kansas City, KS, USA., Prouty M; Department of Dermatology, University of Utah, Salt Lake City, UT, USA., Pathak H; Department of Pathology and Laboratory Medicine, Medical Center, University of Kansas, Kansas City, KS, USA.; Kansas Institute for Precision Medicine, Medical Center, University of Kansas, Kansas City, KS, USA., Puri R; Department of Pathology and Laboratory Medicine, Medical Center, University of Kansas, Kansas City, KS, USA., Mitra A; Department of Pathology and Laboratory Medicine, Medical Center, University of Kansas, Kansas City, KS, USA., Madan R; Department of Pathology and Laboratory Medicine, Medical Center, University of Kansas, Kansas City, KS, USA., Forrest ML; Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, USA., Huang A; Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, USA., Weir S; Institute for Advancing Medical Innovation, Medical Center, University of Kansas, Kansas City, KS, USA., Godwin AK; Department of Pathology and Laboratory Medicine, Medical Center, University of Kansas, Kansas City, KS, USA.; Kansas Institute for Precision Medicine, Medical Center, University of Kansas, Kansas City, KS, USA., Alhakamy NA; Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.; Center of Excellence for Drug Research and Pharmaceutical Industries, King Abdulaziz University, Jeddah, Saudi Arabia.; Mohamed Saeed Tamer Chair for Pharmaceutical Industries, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.; Kinimmune, Inc, St. Louis, MO, USA., Griffin JD; Kinimmune, Inc, St. Louis, MO, USA., Berkland CJ; Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, USA.; Kinimmune, Inc, St. Louis, MO, USA.; Department of Chemical and Petroleum Engineering, University of Kansas, Lawrence, KS, USA. |
| Source: | Translational medicine communications [Transl Med Commun] 2023; Vol. 8. Date of Electronic Publication: 2023 Feb 27. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 101738095 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2396-832X (Electronic) Linking ISSN: 2396832X NLM ISO Abbreviation: Transl Med Commun Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
